James Zinman, MD
Urology · Bloomfield, NJNPI 1578591467
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Acerus Pharmaceuticals Corporation at 39.5% of the total. Reporting peaked in 2022 at $4,311 and has fallen 90.1% since, to $428 in 2025.
Across 201 payments — averaging $53.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acerus Pharmaceuticals Corporation$4K
- Coloplast$2K
- Bayer$1K
- Antares Pharma, Inc.$932
- Astellas Pharma US Inc$680
- Boston Scientific$352
- plus $2K from 24 others
What the payments were for
- Consulting fees$4,97246%
- Travel & lodging$1,30612%
- Food & beverage$3,81335%
- Education$6636%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acerus Pharmaceuticals Corporation | 7 | $4,247 |
| Coloplast | 23 | $1,615 |
| Bayer | 6 | $1,194 |
| Antares Pharma, Inc. | 61 | $932 |
| Astellas Pharma US Inc | 16 | $680 |
| Boston Scientific | 6 | $352 |
| Procept Biorobotics Corporation | 3 | $210 |
| Neotract Inc. | 2 | $184 |
| Johnson & Johnson | 6 | $182 |
| Olympus America Inc. | 2 | $165 |
| Endo Pharmaceuticals Inc. | 10 | $151 |
| Pfizer | 10 | $129 |
| Clarus Therapeutics Inc. | 9 | $111 |
| Myovant Sciences Inc. | 6 | $97 |
| AbbVie | 6 | $81 |
| Dendreon Pharmaceuticals LLC | 4 | $58 |
| AstraZeneca | 3 | $47 |
| Ferring Pharmaceuticals Inc. | 3 | $47 |
| Zyla Life Sciences, Inc. | 3 | $42 |
| Tolmar Pharmaceuticals, Inc. | 3 | $40 |
| Merck | 2 | $31 |
| Amgen | 2 | $28 |
| Halozyme Inc | 1 | $23 |
| 180 Medical, Inc. | 1 | $22 |
| Seapearl East, Inc | 1 | $19 |
| Tolmar, Inc. | 1 | $17 |
| Urovant Sciences Inc | 1 | $15 |
| Aytu Biopharma, Inc. | 1 | $12 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $12 |
| Verity Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Natesto$4,187
- TITAN$1,313
- Nubeqa$1,122
- UroLift$164
- AquaBeam Robotic System$148
- iTIND System$146
- rezum Generator$143
- GENERAL KIDNEY STONE DISEASE$129
How this compares
$10,754 in reported general payments places this provider in the 85th percentile of 401 urology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 49 | $135,864 |
| MyrbetriqMirabegron | 75 | $48,159 |
| XyostedTestosterone Enanthate | 50 | $44,354 |
| Tamsulosin Hcl | 1,380 | $30,808 |
| GemtesaVibegron | 26 | $18,774 |
| Silodosin | 112 | $11,114 |
| Solifenacin Succinate | 140 | $8,660 |
| Finasteride | 411 | $6,588 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 219 | $6,135 |
| Oxybutynin Chloride ErOxybutynin Chloride | 131 | $5,082 |
| Testosterone | 37 | $4,725 |
| Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl | 13 | $3,397 |
| Dutasteride | 88 | $3,031 |
| Methenamine Hippurate | 63 | $2,890 |
| Potassium Citrate ErPotassium Citrate | 24 | $2,862 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $680 | $48,15975 claims |
| Antares Pharma, Inc.Xyosted | $932 | $44,35450 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 401 urology providers in New Jersey.
Other urology in Bloomfield
- Matthew ShahbandiBloomfield$9K
- Michael StifelmanHackensack$1.4M
- Gordon BrownCherry Hill$1.3M
- Thomas MuellerLinwood$1.1M
- David SussmanLinwood$802K
- Michael IngberDenville$530K
- Ravi MunverHackensack$529K
- Grannum SantBridgewater$487K
- Mutahar AhmedMaywood$414K
- Kevin GioiaRumson$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.